NASDAQ: CRMD
CorMedix Inc.
Healthcare · Biotechnology
Market Cap
$680.18M
52w High
$17.43
52w Low
$6.13
P/E
4.45
Volume
2.51M
Outstanding Shares
78.45M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 36.16% over the last year. Revenue grew 384.6% over the trailing twelve months. Operating margin moved from 17.53% to 48.41%.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently 48.41%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally.
Valuation
Stock splits
Every 5 shares became 1
Profitability & growth
Analyst consensus
8
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 6, 2026
Q3 FY26 · EPS est $0.26 · Revenue est $95.62M
View